3-Amino-4,5-dimethyl-thiophen-2-carbonsaeure-methylester | 98593-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-Amino-4,5-dimethyl-thiophen-2-carbonsaeure-methylester
• 英文别名: 3-amino-4,5-dimethyl-thiophene-2-carboxylic acid methyl ester；Methyl 3-amino-4,5-dimethylthiophene-2-carboxylate
• CAS: 98593-57-8
• 化学式: C₈H₁₁NO₂S
• mdl: MFCD03414618
• 分子量: 185.247
• InChiKey: IRHWFQBHNJAQEX-UHFFFAOYSA-N

物化性质

• 熔点：
  154 °C(Solv: methanol (67-56-1))
• 沸点：
  339.2±37.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Amino-4,5-dimethyl-thiophen-2-carbonsaeure-methylester 在 sodium hydroxide 、 甲烷磺酸 作用下， 反应 6.0h， 生成 2,3-Dimethyl-6,7-dihydro-thiazolo[3,2-a]thieno[3,2-d]pyrimidin-9-one
  参考文献：
  名称：

  Condensed thienopyrimidines. II. Synthesis and gastric antisecretory activity of thiazole and polymethylene condensed thienopyrimidine derivatives.

  摘要：

  合成并评估了噻唑并噻吩和嘧啶-5-酮衍生物（6、11和16）以及多亚甲基缩合的噻吩-和嘧啶-5-酮衍生物（19-21），其中在3的噁唑烷环中的氧原子被硫原子或亚甲基取代，并对在幽门结扎大鼠中进行的胃抗分泌活性进行了评估。文中讨论了这些化合物的结构-活性关系。

  DOI：

  10.1248/cpb.37.2122

文献信息

• Condensed thienopyrimidines. I. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidin-5-one derivatives.
  作者：Mitsuo SUGIYAMA、Toshiaki SAKAMOTO、Keiichi TABATA、Kazuo ENDO、Keiichi ITO、Mitsuko KOBAYASHI、Hiroshi FUKUMI

  DOI：10.1248/cpb.37.2091

  日期：——

  A practical preparation of various 2, 3-dihydro-5H-oxazolo[3, 2-a]thieno[3, 2-d]-, [3, 4-d]-, and [2, 3-d]pyrimidin-5-one derivatives was developed starting from the corresponding aminothiopheneesters in two steps, and their chloro-substituted derivatives were prepared. These compounds were evaluated for gastric antisecretory activity in pylorus-ligated rats, compared to the anti-ulcer standard, cimetidine, and their structure-activity relationships are discussed.

  一种实用的方法被开发用于合成多种2, 3-二氢-5H-噁唑并噻吩的[3, 2-a]、[3, 4-d]和[2, 3-d]嘧啶-5-酮衍生物，该过程从相应的氨基噻吩酯出发，仅需两步，并且其氯取代衍生物也被合成。这些化合物在幽门结扎大鼠中评估了其抗胃分泌活性，并与抗溃疡标准药物西咪替丁进行了比较，同时讨论了它们的结构-活性关系。
• [EN] THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS DE TYPE THIÉNOPYRIMIDINE DE PROTÉINES KINASES C ATYPIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2013078126A1

  公开（公告）日：2013-05-30

  The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X如本文所定义。式（I）的化合物及其盐具有PKC抑制活性，并可用于治疗增生性疾病。
• Thienopyrimidine-based inhibitors of the src family
  申请人：——

  公开号：US20040077663A1

  公开（公告）日：2004-04-22

  Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

  各种基于噻唑并嘧啶的类似化合物能够选择性地抑制Src家族的酪氨酸激酶。这些化合物在治疗各种疾病方面非常有用，包括增生性疾病、血液学疾病、骨质疏松症、神经系统疾病、自身免疫疾病、过敏/免疫疾病或病毒感染。
• Thienopyrimidine-based inhibitors of the Src family
  申请人：Board of Regents, The University of Texas System

  公开号：US06503914B1

  公开（公告）日：2003-01-07

  Various thienopyrimidine-based analog compounds that selectively inhibit the Src family of tyrosine kinases. These compounds are thienopyrimidines and contain a hydrozone bridge created by heating a thienopyrimidine hydrazine with an aldehyde in ethanol at reflux. Such compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

  各种基于噻唑嘧啶的类似化合物，可以选择性地抑制Src酪氨酸激酶家族。这些化合物是噻唑嘧啶，并含有由在乙醇中回流时将噻唑嘧啶肼和醛加热而形成的羟肼桥。这些化合物可用于治疗各种疾病，包括增生性疾病、血液学疾病、骨质疏松症、神经系统疾病、自身免疫疾病、过敏/免疫疾病或病毒感染。
• Thienopyrimidine Inhibitors of Atypical Protein Kinase C
  申请人：Cancer Research Technology Limited

  公开号：US20140323435A1

  公开（公告）日：2014-10-30

  The present application provides a compound of formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

  本申请提供了公式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X的定义如本文所述。公式（I）的化合物及其盐具有aPKC抑制活性，可用于治疗增殖性疾病。